Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS’ Predictive ...

GPGI, Inc. (NYSE:GPGI) Q4 2025 Earnings Call Transcript March 12, 2026 GPGI, Inc. misses on earnings expectations. Reported EPS is $0.23 EPS, expectations were $0.2336. Operator: Good day, and thank ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2025 Earnings Call Transcript March 12, 2026 Corvus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.15451 EPS, expectations ...

BMW Group and above all, one that set our course for the future. First, we achieved a solid financial result with group earnings of more than EUR 10 billion. Walter Mertl will provide more detail in ...

Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS' Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilize ...

Major Chinese technology companies, including Tencent Holdings and TikTok's parent company ByteDance, are competing fiercely ...

Zevra Therapeutics, Inc. is rated a Buy, delivered robust FY25 results, with 350% revenue growth to $106.5M. Learn more about ZVRA stock here.

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial ...

Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory ...

BELO HORIZONTE, Brazil, March 13, 2026--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider ...